Abstract 977P
Background
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor globally, Hence, there is an urgent need for safer and more effective options to improve the survival rates of HCC patients. This study aims to evaluate the viability, efficacy, and safety of HAIC and Regorafenib combined with PD-1 inhibitors for treating advanced HCC patients.
Methods
This is a multicenter, randomized controlled clinical study of hepatocellular carcinoma. Eligible individuals with unresectable HCC were randomized into either the HAIC combined with regorafenib and PD-1 inhibitors group (HAIC+REG+ICIs group) or the regorafenib combined with PD-1 inhibitors group (REG+ICIs group). The primary endpoint is the objective response rate (ORR). Secondary endpoints include PFS, OS, DCR (all assessed by BICR per RECIST v1.1), and safety.
Results
Up to April 24, 2023, a total of 45 patients were enrolled and all patients are available for analysis. The HAIC+REG+ICIs group and the REG+ICIs group included 28 and 17 patients, respectively.The median age were 52.5 years (range, 32-68) and 47.0 years (range, 24-79), 92.9% and 94.1% were male for each group, the proportions of child-pugh A/B were 64.3%/35.7% vs. 88.2%/11.8%; and the patients with China Liver Cancer Staging (CNLC) Ib/IIa/IIb/IIIa/IIIb/IV stage were 0.0%/3.6%/35.7%/21.4%/32.1%/7.1% vs. 5.9%/11.8%/47.1%/11.8%/17.6%/5.9%, respectively. All patients were infected with HBV. The median follow-up time was 16.6 months (1-21.2). The ORR was 39.3% (11/28) and 29.4%(5/17) for HAIC+REG+ICIs group and the REG+ICIs group, P=0.502. DCR was 82.1%(23/28) and 52.9%(9/17) respectively, P=0.036. The median OS of HAIC+REG+ICIs group was significant longer than REG+ICIs group (19.1 vs. NA months, P=0.03; HR=0.039 95% CI: 0.101-0.941). This study is currently ongoing.
Conclusions
HAIC combined with Regorafenib and PD-1 inhibitors compared with Regorafenib and PD-1 inhibitors showed a better tumor response rate, but there was no significant difference. However HAIC combined with regorafenib and PD-1 inhibitors can significantly prolong the overall survival of second-line HCC patients.
Clinical trial identification
ChiCTR2100046555.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18